



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/811,359	03/16/2001	Taeyoung Yoon	49662 [72021]	7721
21874	7590	08/22/2007		
EDWARDS ANGELL PALMER & DODGE LLP			EXAMINER	
P.O. BOX 55874			MURRAY, JEFFREY H	
BOSTON, MA 02205				
			ART UNIT	PAPER NUMBER
			1624	
			MAIL DATE	DELIVERY MODE
			08/22/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	09/811,359		YOON ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Jeffrey H. Murray		1624	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 30 May 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,3-22,30,35,39-64,67 and 69 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3-22,30,35,39-64,67 and 69 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |  |
|--|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)                          |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____   |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application                |
| Paper No(s)/Mail Date. _____   | 6) <input checked="" type="checkbox"/> Other: <u>STN prior art information</u> . |

### **DETAILED ACTION**

Applicant's amendment of May 30, 2007 has been fully considered. This action is in response to a response to a non-final action filed on August 10, 2006. Currently, Claims 2, 23-29, 31-34, 36-38, 65, 66 and 68 are cancelled and Claims 1, 3-22, 30, 35, 39-64, 67 and 69 are considered herein.

1. It is acknowledged that applicants have amended Claim 30 to avoid the 112, 2<sup>nd</sup> rejection.
2. It is acknowledged that applicants have amended Claim 3, 9, 14, 17, and 22 to avoid the 102(b) rejection.

### ***New Grounds for Rejection***

#### ***Claim Rejections - 35 USC § 112, 1st***

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1, 3-22, 30, 35, and 69 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for compounds or compositions with a pyrimidine that contains a substituted phenyl in the 2-position (Ar), an alkoxy group in the 4-position, and a dialkylamino group in the 5-position (R<sup>2</sup>), does not reasonably provide enablement for all of the compounds

Art Unit: 1624

and residue groups listed within the Claims, including most of the functional groups found in R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosures in the application coupled with information known in the art without undue experimentation. (*United States v. Teletronics Inc.*, 8 USPQ2d 1217 (Fed. Cir. 1988)). Whether undue experimentation is needed is not based on a single factor, but rather a conclusion reached by weighing many factors (See *Ex parte Forman* 230 USPQ 546 (Bd. Pat. App. & Inter. 1986) and *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988)). These factors include the following:


1) *Amount of guidance provided by Applicant.* While the Applicant has demonstrated within the application how to make 2-substituted phenyl-4-alkoxy-5-dialkylamino pyrimidines, the generic Claims 1, 3, 9, and 15 are massive, and no reference is made as to how to synthesize any compounds that contain all the various and multiple R groups that are listed within these Claims other than the groups aforementioned. Page 33-34 of the specification provides three different Schemes for synthesizing all of the various final compounds.

Applicants point to a 1983 Journal of Organic Chemistry paper to synthesize the starting materials of Compound IV. However this journal article does not provide the details on how to synthesize all of the millions of starting materials needed to make each and every compound claimed throughout this application.

2) *Unpredictability in the art.* It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved", and physiological activity is generally considered to be an unpredictable factor. (USPQ 18, 24 (CCPA 1970). See *In re Fisher*, 427 F.2d 833, 839, 166.

Page 33-34 of the specification provides three different Schemes for synthesizing all of the various final compounds. In each Scheme, a reduction step (as well as an additional reductive amination step in two of the Schemes) takes place with the R<sup>1</sup> and R<sup>3</sup> groups present. Yet the possible substituents listed for R<sup>1</sup> and R<sup>3</sup> include cyano, nitro, substituted or unsubstituted alkenes and alkynes, alkylsulfinyl and alkylsulfonyl groups and carboxamides. In one particular instance (that of reducing a nitro group), the exact group being reduced is also listed as an R group which is may be present during that reduction. This is clearly not possible. For example, a sodium triacetoxyborohydride reaction can cause the hydroboration of alkenes, (Gribble, et. al., p. 9) while the palladium on carbon reduction is notorious for reducing the double and triple bonds of alkenes, alkynes, and nitriles as well as potentially removing a halogen from an aromatic or pyrimidine ring. (King, et. al. pp. 1-3, 7). The literature and arguments presented here clearly show that a vast majority of the potential R groups cannot exist under the present application's reaction conditions.

3) *Breadth of the claims.* The scope of the claims involve all of the millions of compounds of general formula (I):



whereby Ar, R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> are defined within the specification. Thus, the scope of claims is incredibly broad.

4) *Nature of the invention.* The nature of the invention relates generally to novel substituted 2-arylpyrimidine compounds that bind with high selectivity and/or high affinity to CRF1 receptors.

5) *Level of skill in the art.* The artisan using Applicants invention would be a chemist with a Ph.D. degree, and having several years of laboratory bench experience.

MPEP §2164.01 (a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here that Applicant is not enabled for making most of the compounds or compositions mentioned in the current application.

***Claim Rejections - 35 USC § 102***

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this

Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Christensen, et. al., Journal of Organic Chemistry, (1971), 36(17), pp.2462-6.

The currently claimed compounds read on the compound of the prior art.

Whereby the structure contains a pyrimidine with a phenyl in the 2-position, a methoxy group in the 4- and 6-positions, and a nitro group in the 5-position. See CA reference # 29939-35-3.

3. Claim 3, 5, 15, 16 is rejected under 35 U.S.C. 102(b) as being anticipated by Kameko, et. al., JP 10237447, which was published on September 8, 1998.

The currently claimed compounds read on the compounds of the prior art.

Whereby the structure contains a pyrimidine with a para-hexylphenyl in the 2-position, a hydrogen in the 4- and 6-positions, and an octoxy group in the 5-position. See CA reference # 155430-65-2.

***Claim Rejections - 35 USC § 103***

18. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1624

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

19. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

20. Claims 1, 3-22, 30, 35, 39-64 and 69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kleemann et. al. in view of Hoefle et. al.

The current application recites a variety of specific novel substituted 2-arylpyrimidine compounds that bind with high selectivity and/or high affinity to CRF1 receptors. These compounds all contain a substituted phenyl in the 2-position (Ar), an alkoxy group in the 4-position, and a dialkylamino group in the 5-position (R<sup>2</sup>).

The patent reference Kleemann et. al. teaches a group of compounds which are similar in scope to the current application. Within Kleemann et. al., (See Formula I, col.1) the same core structure is present which teach these compounds as being used for a similar purpose as the proposed application. That is, the 2-arylpyrimidine compounds were synthesized and tested to be used as an herbicidal agent.



Art Unit: 1624

Kleemann et. al. has an identical core structure to the current patent application with one major difference. Kleemann et. al. teaches an aryloxy group in the 4-position, not the alkoxy group taught by the present application.

The patent reference, Hoefle et. al., teaches a group of compounds which are similar in scope to the current application. Within Hoefle et. al. (col. 2), a similar core structure is present which teaches these compounds with one difference from the current application. The patent reference compounds are missing a substituted phenyl ring in the 2-position. That is, the reference compounds contain a pyrimidine with a alkoxy group in the 4- and 6-positions, and an amino group in the 5-position, both of which would fall under the current applicants' Claims. However the compounds contain a hydrogen in the 2-position in place of a substituted phenyl ring.

Relating this information to the Kleemann et. al. patent, it would have been obvious for a person of ordinary skill in the art to try replacing the aryloxy group in the 4-position of the Kleemann patent with an alkyloxy group such as the one discussed in the Hoefle patent at the same position on the pyrimidine ring in an attempt to obtain a compound or composition which possesses enhanced activity and to afford a positive benefit from the replacement.

### ***Conclusion***

Claims 1, 3-22, 30, 35, 39-64 and 69 are rejected.


Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey H. Murray whose telephone number is (571) 272-9023. The examiner can normally be reached on Mon.-Thurs. 7:30-6pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


JHM




JAMES O. WILSON  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

To Be Mailed


LS ANSWER 19 OF 565 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Pyrimidine, 5-(2-methylbutoxy)-2-[4-(octyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 218770-20-8 CAPLUS  
CN Pyrimidine, 5-(2-methylbutoxy)-2-[4-(nonyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 218770-21-9 CAPLUS  
CN Pyrimidine, 2-[4-(decyloxy)phenyl]-5-(2-methylbutoxy)- (9CI) (CA INDEX NAME)




RN 218770-22-0 CAPLUS  
CN Pyrimidine, 5-(2-methoxyethoxy)-2-[4-(2-methylbutoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 218770-23-1 CAPLUS  
CN Pyrimidine, 5-(2-ethoxyethoxy)-2-[4-(2-methylbutoxy)phenyl]- (9CI) (CA INDEX NAME)




LS ANSWER 20 OF 565 CAPLUS COPYRIGHT 2007 ACS on STN  
IT 155430-65-2 155430-66-3 155430-67-4 155430-68-5  
RI: DEV (Device component use); USES (Uses)  
(ferroelec. liquid crystal display device with large temperature-dependency of self-polarization)  
RN 155430-65-2 CAPLUS  
CN Pyrimidine, 5-[(2-fluorooctyl)oxy]-2-(4-hexylphenyl)- (9CI) (CA INDEX NAME)




RN 155430-66-3 CAPLUS  
CN Pyrimidine, 5-[(2-fluorooctyl)oxy]-2-(4-heptylphenyl)- (9CI) (CA INDEX NAME)




RN 155430-67-4 CAPLUS  
CN Pyrimidine, 5-[(2-fluorooctyl)oxy]-2-(4-octylphenyl)- (9CI) (CA INDEX NAME)




RN 155430-68-5 CAPLUS  
CN Pyrimidine, 5-[(2-fluorooctyl)oxy]-2-(4-nonylphenyl)- (9CI) (CA INDEX NAME)




LS ANSWER 19 OF 565 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 218770-24-2 CAPLUS  
CN Pyrimidine, 5-(2-butoxyethoxy)-2-[4-(2-methylbutoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 218770-25-3 CAPLUS  
CN Pyrimidine, 2-[4-(2-methoxyethoxy)phenyl]-5-(2-methylbutoxy)- (9CI) (CA INDEX NAME)



RN 218770-26-4 CAPLUS  
CN Pyrimidine, 2-[4-(2-ethoxyethoxy)phenyl]-5-(2-methylbutoxy)- (9CI) (CA INDEX NAME)





RN 218770-27-5 CAPLUS  
CN Pyrimidine, 2-[4-(2-butoxyethoxy)phenyl]-5-(2-methylbutoxy)- (9CI) (CA INDEX NAME)



LS ANSWER 20 OF 565 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1998:586487 CAPLUS  
 DOCUMENT NUMBER: 129:268250  
 TITLE: Ferroelectric liquid-crystal composition,  
 ferroelectric liquid-crystal device, and its driving  
 method  
 INVENTOR(S): Kaneko, Takeshi; Koden, Mitsuhiro; Okabe, Eiji;  
 Shunto, Tatsuji; Saito, Shinichi; Saito, Hideo  
 PATENT ASSIGNEE(S): Sharp Corp., Japan; Chisso Corp.  
 SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10237447	A	19980908	JP 1997-46528	19970228
PRIORITY APPLN. INFO.:			JP 1997-46528	19970228
OTHER SOURCE(S):		MARPAT 129:268250		

GI



AB The composition contains an aromatic compound I (R1 = C4-16 alkyl; R2 =  
 C2-12 alkyl), II (R3, 4 = C1-15 alkyl, alkoxy; A = Ph, C6H8, direct bond), and  
 III (R5, 6 = C1-18 alkyl, alkoxy; X = H, F). The device contains the  
 composition. Driving method of the device is also claimed. The composition  
 shows large temperature-dependency of self-polarization, so that the device shows  
 small temperature-dependency of response speed and wide temperature margin.

To Be Mailed

L24 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1971:510265 CAPLUS <<LOGINID::20070815>>  
DOCUMENT NUMBER: 75:110265  
TITLE: Reaction of 4,6-dimethoxy-5-nitropyrimidine with  
methylhydrazine. Formation of 4-hydrazine-6-  
hydroxypyrimidine  
AUTHOR(S): Christensen, Bert E.; Stahl, Quade; Lehmkuhl, Frank  
CORPORATE SOURCE: Dep. Chem., Oregon State Univ., Corvallis, OR, USA  
SOURCE: Journal of Organic Chemistry (1971), 36(17), 2462-6  
CODEN: JOCEAH; ISSN: 0022-3263  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 75:110265  
AB Reaction of 4,6-dimethoxy-5-nitropyrimidine (I) with MeNHNH2 in refluxing  
pyridine or BuOH involves methylation of the solvent by I and the  
nucleophilic substitution and demethylation of the methylhydrazino  
substituent in the 5 position to yield 4-hydrazino-6-hydroxypyrimidine.  
The first step in this sequence of reactions involves the methylation of  
the solvent, followed by nucleophilic substitution of methylhydrazine in  
the 4 position, migration of its Me substituent to form C to O bond with  
the adjacent nitro substituent, and eventual elimination of Me nitrite  
from the 5 position as one of the reaction products. 4,6-Dimethoxy-5-  
nitropyrimidine reacts with pyridine (in the absence of MeNHNH2) to yield  
an insol. methylpyridium salt which is not a precursor of  
4-hydrazino-6-hydroxypyrimidine. The mother liquor from this reaction on  
acid hydrolysis yields 4-hydroxy-6-methoxy-5-nitropyrimidine and reacts  
with MeNHNH2 to yield 4-hydroxy-6-hydrazinopyrimidine. Both  
4-chloro-6-hydroxy-5-nitropyrimidine and 4,6-dichloro-5-nitropyrimidine  
react with MeNHNH2 in alc. to yield the corresponding methylhydrazino  
derivs.  
IT 29939-35-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 29939-35-3 CAPLUS  
CN Pyrimidine, 4,6-dimethoxy-5-nitro-2-phenyl- (CA INDEX NAME)

